title: Etoricoxib-induced erythema-multiforme-like eruption.
abstract: Etoricoxib is a new, highly selective cyclooxygenase (COX) 2 inhibitor, reported to have an increased cutaneous and systemic safety profile compared to the previous COX-2 inhibitors, including celecoxib, rofecoxib and valdecoxib. To the best of our knowledge, the present case of etoricoxib-induced erythema-multiforme-like eruption is the first reported in the literature.
authors.affiliation: Department of Dermatopathology, University Medical Center of Liège, Liège, Belgium.
authors.forename: Laurence
authors.initials: L
authors.lastname: Thirion
authors.forename: Arjen F
authors.initials: AF
authors.lastname: Nikkels
authors.forename: Gérald E
authors.initials: GE
authors.lastname: Piérard
mesh_terms: D000368:Aged; D001168:Arthritis / Q000188:drug therapy; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D004892:Erythema Multiforme / Q000139:chemically induced* / Q000473:pathology; D000077613:Etoricoxib; D006801:Humans; D008297:Male; D011725:Pyridines / Q000009:adverse effects*; D012867:Skin / Q000473:pathology; D013450:Sulfones / Q000009:adverse effects*
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D011725:Pyridines; D013450:Sulfones; D000077613:Etoricoxib